logo
7 Steps To AI-Proof Your Resume And Land More Job Interviews

7 Steps To AI-Proof Your Resume And Land More Job Interviews

Forbes27-05-2025
A whopping 99% of hiring managers now use AI in their recruitment process, according to Insight Global's 2025 AI in Hiring Survey Report. Meanwhile, most job seekers get filtered out by Applicant Tracking Systems (ATS) before a human recruiter ever lays eyes on their resume. If you're wondering why your applications vanish into a digital black hole instead of landing you job interviews, it's time to AI-proof your resume.
When you understand how ATS technology works and apply specific formatting and content strategies, you can dramatically boost your chances of reaching actual humans. Here are seven steps to AI-proof your resume and land more job interviews.
ATS algorithms prioritize exact job title matches. In fact, research from Jobscan, analyzing over 2.5 million resumes, found that candidates who included the same job title as the posting were 10.6 times more likely to get a job interview. If you're applying for "Digital Marketing Manager," use that exact phrase in your resume header or professional summary rather than "Online Marketing Leader" or similar variations.
Also, extract three to five key phrases that appear repeatedly throughout the job description. Common examples include:
For acronyms and technical terms, include both the whole phrase and abbreviation: "Customer Relationship Management (CRM)" or "Search Engine Optimization (SEO)." This ensures you're found whether recruiters search for the acronym or complete phrase. Finally, remember only to include terms that genuinely reflect your experience. According to Insight Global's research, 88% of hiring managers can detect AI-enhanced job applications, and 54% care if candidates use it.
Copy the job description into a word cloud generator to identify the most frequently mentioned terms visually. The largest words are your priority keywords.
Since recruiters spend just seconds reviewing each resume, your most valuable qualifications need immediate visibility. A well-crafted "Core Skills" section gives both ATS systems and human reviewers instant access to your key competencies. Position this section below your contact information and professional summary.
Structure it as a clean, scannable list combining:
Research shows recruiters filter by skills 76% of the time when searching ATS databases. By front-loading your most relevant capabilities, you increase the likelihood that your resume surfaces in these targeted searches.
Organize your skills by relevance to the job posting, not alphabetically. Place the most critical skills first, as recruiters often scan only the beginning of lists.
Research shows that including specific numbers in your resume substantially increases your chances of landing a job interview. Transform generic statements into quantified achievements.
Focus on these metrics:
Instead of "improved sales performance," specify "increased quarterly sales by 32%, generating an additional $2.4 million in revenue." Rather than "managed a team," write "led a cross-functional team of 12 professionals across three departments."
Use the "Challenge-Action-Result" framework for each achievement. Start with the problem you faced, describe your specific action, and then quantify the positive outcome.
Creative section titles confuse ATS systems and frustrate recruiters who expect conventional resume organization. Stick to universally recognized headings that both algorithms and humans can understand.
Use these standard section titles:
Avoid creative alternatives like "My Journey," "Professional Toolkit," or "Where I've Made an Impact." Recruiters spend most of their time studying the work experience section. When they can't quickly locate this information due to unconventional headings, you will soon lose their attention.
Test your section headings by asking someone unfamiliar with your background to scan your resume quickly. If they can't immediately understand what each section contains, your headings need simplification.
File format can determine whether your resume is parsed correctly or completely misread by ATS systems. The safest default choice is .docx format unless the job posting specifically requests otherwise.
Consider these format guidelines:
Save your resume with an explicit, professional filename that includes your name and the word "resume" (e.g., "JohnSmith_Resume_2025.docx").
While visually striking resumes might catch human attention, they often confuse ATS systems and can result in your qualifications being completely misread or ignored. Complex formatting elements, such as tables, text boxes, graphics, and unusual fonts, can cause parsing errors.
Instead, use standard fonts like Arial, Calibri, Times New Roman or Helvetica in 10-to 12-point sizes. Maintain consistent formatting throughout your document.
Copy and paste your resume into a plain text editor (like Notepad) to see how an ATS might read it. If the information looks scrambled, simplify your formatting.
Before submitting your job application, test your resume's ATS compatibility using online simulation tools. Platforms like Jobscan and Resume Worded offer free ATS simulation services that provide detailed feedback on keyword optimization, formatting issues and overall match scores.
These simulators typically analyze:
Target a match rate of 80% or higher, which indicates a strong alignment between your resume and the target position. Use this feedback to refine your resume before submission. If the tool indicates low keyword matching, revisit the job description to identify additional relevant terms you can incorporate.
Run your resume through multiple ATS simulators to get a comprehensive view of potential issues. Each tool may catch different problems.
While ATS optimization is crucial for getting your resume seen, remember that most hiring managers still emphasize the importance of human involvement in the hiring process. The most effective resumes strike a balance between technical optimization and authentic storytelling. By implementing these seven steps, you'll ensure your resume not only survives the initial digital screening but also compels recruiters to schedule that crucial first job interview.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share
XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share

Yahoo

time22 minutes ago

  • Yahoo

XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share

CHICAGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- XAI Madison Equity Premium Income Fund (the 'Fund'), has declared its regular monthly distribution of $0.060 per share on the Fund's common shares (NYSE: MCN) payable on September 2, 2025. The amount represents no change from the previous month's distribution amount. As mentioned in previous distribution declarations, the Fund has changed its distribution frequency from quarterly to monthly, which went into effect with the April 1, 2025 declaration. XA Investments believes this change enables investors to better manage their cash flow needs. Ex-Dividend Date August 15, 2025 Record Date August 15, 2025 Payable Date September 2, 2025 Amount $0.060 per share Change from Previous Month No Change The following dates apply to the declaration: Common share distributions may be paid from net investment income (regular interest and dividends), capital gains and/or a return of capital. The specific tax characteristics of the distributions will be reported to the Fund's common shareholders on Form 1099 after the end of the 2025 calendar year. Shareholders should not assume that the source of a distribution from the Fund is net income or profit. For further information regarding the Fund's distributions, please visit . The Fund's net investment income and capital gain can vary significantly over time; however, the Fund seeks to maintain more stable common share quarterly distributions over time. The Fund's final taxable income for the current fiscal year will not be known until the Fund's tax returns are filed. As a registered investment company, the Fund is subject to a 4% excise tax that is imposed if the Fund does not distribute to common shareholders by the end of any calendar year at least the sum of (i) 98% of its ordinary income (not taking into account any capital gain or loss) for the calendar year and (ii) 98.2% of its capital gain in excess of its capital loss (adjusted for certain ordinary losses) for a one-year period generally ending on December 31 of the calendar year (unless an election is made to use the Fund's fiscal year). In certain circumstances, the Fund may elect to retain income or capital gain to the extent that the Board of Trustees, in consultation with Fund management, determines it to be in the interest of shareholders to do so. The common share distributions paid by the Fund for any particular period may be more than the amount of net investment income from that period. As a result, all or a portion of a distribution may be a return of capital, which is in effect a partial return of the amount a common shareholder invested in the Fund, up to the amount of the common shareholder's tax basis in their common shares, which would reduce such tax basis. Although a return of capital may not be taxable, it will generally increase the common shareholder's potential gain, or reduce the common shareholder's potential loss, on any subsequent sale or other disposition of common shares. Future common share distributions will be made if and when declared by the Fund's Board of Trustees, after the evaluation of several factors, including the Fund's net investment income, financial performance and available cash. There can be no assurance that the amount or timing of common share distributions in the future will be equal or similar to that described herein or that the Board of Trustees will not decide to suspend or discontinue the payment of common share distributions in the future. The Fund's objective is to achieve a high level of current income and current capital gains, with long-term capital appreciation as a secondary objective. The Fund intends to pursue its objective by investing in a portfolio of common stocks and utilizing an option strategy, primarily by writing (selling) covered call options on a substantial portion of the common stocks in the portfolio in order to generate current income and gains from option writing premiums and, to a lesser extent, from dividends. Market action can impact dividend issuance as the Fund's total assets affect the Fund's future dividend prospects. The Fund provides additional information on its website at . About XA Investments XA Investments LLC ('XAI') serves as the Fund's investment adviser. XAI is a Chicago-based firm founded by XMS Capital Partners in 2016. XAI serves as the investment adviser for two listed closed-end funds and an interval closed-end fund. The listed closed-end funds, the XAI Octagon Floating Rate & Alternative Income Trust and XAI Madison Equity Premium Income Fund both trade on the New York Stock Exchange and the interval fund, Octagon XAI CLO Income Fund is available via direct subscription and through select broker/dealers and wealth management platforms. In addition to investment advisory services, the firm also provides investment fund structuring and consulting services focused on registered closed-end funds to meet institutional client needs. XAI offers custom product build and consulting services, including development and market research, sales, marketing, and fund management. XAI believes that the investing public can benefit from new vehicles to access a broad range of alternative investment strategies and managers. XAI provides individual investors with access to institutional-caliber alternative managers. For more information, please visit . About XMS Capital Partners XMS Capital Partners, LLC, established in 2006, is a global, independent, financial services firm providing M&A, corporate advisory and asset management services to clients. It has offices in Chicago, Boston and London. For more information, please visit . About Madison Investments Madison Investments is an independent investment management firm based in Madison, WI. The firm was founded in 1974, has approximately $28.3 billion in assets under management as of March 31, 2025, and is recognized as one of the nation's top investment firms. Madison offers domestic fixed income, U.S. and international equity, covered call, multi-asset, insurance and credit union investment management strategies. For more information, please visit .Madison and/or Madison Investments is the unifying tradename of Madison Investment Holdings, Inc., Madison Asset Management, LLC, and Madison Investment Advisors, LLC. Madison Funds are distributed by MFD Distributor, LLC. Madison is registered as an investment adviser with the U.S. Securities and Exchange Commission. MFD Distributor, LLC is registered with the U.S. Securities and Exchange Commission as a broker-dealer and is a member firm of the Financial Industry Regulatory Authority . XAI does not provide tax advice; please consult a professional tax advisor regarding your specific tax situation. Income may be subject to state and local taxes, as well as the federal alternative minimum tax. Investors should consider the investment objectives and policies, risk considerations, charges and expenses of the Fund carefully before investing. For more information on the Fund, please visit the Fund's webpage at . This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction. NOT FDIC INSURED NO BANK GUARANTEE MAY LOSE VALUE Media Contact:Kimberly Flynn, PresidentXA Investments LLCPhone: 888-903-3358Email: KFlynn@ in to access your portfolio

US securities regulator announces AI task force
US securities regulator announces AI task force

Yahoo

time22 minutes ago

  • Yahoo

US securities regulator announces AI task force

(Reuters) -The U.S. Securities and Exchange Commission said on Friday that it is creating an artificial intelligence task force to lead the agency's efforts to "enhance innovation and efficiency" in its operations. Valerie Szczepanik, who has been named the SEC's chief AI officer, will lead the task force, the regulator said in a statement. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Yahoo

time22 minutes ago

  • Yahoo

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million. TD Cowen and BMO Capital Markets acted as joint book-running managers for the offering. The shares of common stock were offered by Prime Medicine pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Investor and Media ContactsGregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store